Autoantibody in the systemic sclerosis (SS);Auto-Anticorpos na esclerose sistêmica (ES)

Revista Brasileira de Reumatologia

Volumn 44, Issue 3, 2004, Pages 215-223

  Andrade, Luís Eduardo Coelho ^a   Leser, Paulo Guilherme ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

Author keywords

Antinuclear antibody; Autoantibody; Scleroderma; Systemic sclerosis (SE)

Indexed keywords

EID: 77956672257     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Harvey GR, Black C, Maddison PJ, McHugh NJ: Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24: 477-84, 1997.
2. McHugh NJ Harvey GR, Whyte J, Dorsey JK: Segregation of autoantibody with disease in monozygotic twin pairs discordant for systemic sclerosis. Three further cases. Arthritis Rheum 38: 1845-50, 1995.
3. Catoggio LI, Skinner RP, Madisson PJ: Frequency and clinical significance of anticentromere and anti-Scl-70 antibodies in an English connective tissue disease population. Rheumatol Int 3: 19-21, 1983.
4. Chang HL, Lee YS, Hong HS, Kuo IT: Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19: 298-302, 1994.
5. Kallenberg CGM, Pastoor GW, Woulda AA, The TH: Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41: 382-7, 1982.
6. Parveen S, Marshed SA, Nishioka M: High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 10: 438-45, 1995.
7. Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Geiyo F: Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol 27: 1403-7, 2000.
8. Zuber M, Golzen R, Filler I: Clinical correlation of anticentromere antibodies. Clin Rheumatol 13: 427-32, 1994.
9. Vazquez-Abad D, Rothfield NF: Autoantibodies in systemic sclerosis. Int Rev Immunol 12: 145-57, 1995.
10. Earnshaw WC, Sullivan KF, Machlin PS, et al: Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen. J Cell Biol 104: 817-29, 1987.
11. Earnshaw WC, Machlin PS, Bordwell BJ, Rothfield NF, Cleveland DW: Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. Proc Natl Acad Sci USA 84: 4979-83, 1987.
12. Genth E, Mierau R, Genetzky P, et al: Immunogenetic association of scleroderma-related antinuclear antibodies. Arthritis Rheum 33: 657-65, 1990.
13. Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, Arnett FC: Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anti-centromere autoantibody response in systemic slcerosis (scleroderma). J Clin Invest 89: 1208-13, 1992.
14. Mcneilage LJ, Youngchaiyud U, Whittingham S: Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 32: 54-60, 1989.
15. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA, Wright TM: Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase antibody. Arthritis Rheum 42: 465-74, 1999.
16. Aeschlimann A, Meyer O, Bourgeois P, et al: Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis and clinical correlation. Ann Rheum Dis 48: 992-7, 1989.
17. Spencer-Green G, Alter D, Welsch HG: Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 103: 242-8, 1977.
18. Riboldi P, Asero R, Origgi L, et al: Antinuclear antibodies in progressive systemic sclerosis. Clin Immunol Immunopathol 3: 205-11, 1985.
19. Jablonska S, Blaszczyk M, Jarzabek-Chorzelska M, Chorzelski T, Kalacinska-Strasz Z: Immunological markers of the subsets of systemic scleroderma and its overlap. Arch Immunol Ther Exp (Warsz) 39: 381-90, 1991.
20. Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr.: Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27: 125-31, 1984.
21. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC: Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 35: 216-8, 1992.
22. Weiner ES, Hildebrandt S, Senecal J-L, et al: Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 34: 68-77, 1991.
23. Bryan C, Howard Y, Brennan P, Black C, Silman A: Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35: 1122-6, 1996.
24. Giordanno M, Valentini G, Migliaresi S, Picillo U, Vatti M: Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13: 911-6, 1986.
25. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M: Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37: 75-83, 1994.
26. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T: Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43: 1074-84, 2000.
27. Sato S, Hamaguchi Y, Hasegawa M, Takehara K: Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology Oxford 40: 1135-40, 2001.
28. Weiner ES, Earnshaw WC, Senecal J-L, Bordwell B, Johnson P, Rothfield NF: Clinical association of anti-centromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 31: 378-85, 1988.
29. Rothfield NF, Kurtzmann S, Vazquez-Abad: Association of antitopoisomerase I antibodies with cancer (Letter). Arthritis Rheum 35: 724, 1992.
30. Kyndt X, Hebbar M, Queyrel V, Hachulla E, Hatron PY, Devulder B: Sclérodermie systémique et cancer. Recherche de marqueurs prédictifs des cancers chez 123 patients atteints de Sclérodermie. Rev Med Interne 18: 528-32, 1997.
31. Rizou C, Ioannidis JPA, Panou-Pamonis E, et al: B cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis. Am J Respir Cell Mol Biol 22: 344-51, 2000.
32. Reveille JD, Durban E, MacLeod S, et al: Association of amino acid sequences in the HLA-DQB1 first domain with anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 90: 973-80, 1992.
33. McHugh NJ, Whyte J, Harvey G, Haustein U-F: Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity. Arthritis Rheum 37: 1198-205, 1994.
34. Nietert PI, Sutherland SE, Silver RM, Pandey JP, Dosemecy M: Solvent oriented hobbies and the risk of systemic sclerosis. J Rheumatol 26: 2369-72, 1999.
35. Muryoi T, Kasturi KN, Kafina MJ, et al: Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with the same epitopes. J Exp Med 175: 1103-9, 1992.
36. Tan FK, Arnett FC, Antohi S, et al: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 163: 1066-72, 1999.
37. Kuwama M, Kaburaki J, Mimori T, Tojo T, Homma M: Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91: 1399-404, 1993.
38. Okano Y, Steen VD, Medsger TA: Autoantibody to U3 nucleolar ribonucleoprotein fibrillarin in patients with systemic sclerosis. Arthritis Rheum 35: 95-100, 1992.
39. Arnett FC, Reveille JD, Goldstein R, et al: Autoantibodies to fibrillarin in systemic sclerosis scleroderma. Arthritis Rheum 39: 1151-60, 1996.
40. Mitri GM, Lucas M, Fertig N, Stenn VD, Medsger TA: A comparison between anti-Th/To and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 481: 203-9, 2003.
41. Chan EKL, Imai H, Hamel JC, Tan EM: Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR and ribosomal transcription upstream binding factor. J Exp Med 174: 1239-44, 1991.
42. Dagher JH, Scheer U, Voit R, et al: Autoantibodies to NOR 90/ hUBF: longterm clinical and serological folowup in a patients with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 29: 1543-47, 2002.
43. Imai H, Fritzler MJ, Neri R, Bombardieri S, Tan EM, Chan EK: Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Two MR forms of NOR-90/hUBF autoantigens. Mol Biol Reports 19: 115-24, 1994.
44. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 35: 1211-7, 1992.
45. Mimori T: Structures targeted by the immune system in myositis. Curr Opin Rheumatol 8: 521-7, 1996.
46. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al: Clinical, serologic and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 40: 1257-66, 1997.
47. Pope JE: Scleroderma overlap syndromes. Curr Opin Rheumatol 14: 704-10, 2002.
48. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ: Clinical and serologic associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 117: 395-402, 1999.
49. Jacobsen S, Halberg P, Ullman S, et al: Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 37: 39-45, 1998.
50. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr: Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 37: 902-6, 1994.
51. Pope JE, Thompson A: The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 27: 1450-2, 2000.
52. Schoenroth L, Fritzler MJ: Antibodies to beta2 glycoprotein I and cardiolipin in SSc. Ann Rheum Dis 61: 183-4, 2002.
53. McHugh NJ, James IE, Fairburn K, Maddison PJ: Autoantibodies to mitochondrial and centromere antigens in primary biliary cirrhosis and systemic sclerosis. Clin Exp Immunol 81: 244-9, 1990.
54. Dick T, Mierau R, Bartz-Bazzanellla P, et al: Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61: 121-7, 2002.